181 related articles for article (PubMed ID: 38363332)
1. PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions.
Kwe J; Baunacke M; Boehm K; Platzek I; Thomas C; Borkowetz A
World J Urol; 2024 Feb; 42(1):84. PubMed ID: 38363332
[TBL] [Abstract][Full Text] [Related]
2. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
4. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
5. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
6. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
7. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
[TBL] [Abstract][Full Text] [Related]
8. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
Haack M; Miksch V; Tian Z; Duwe G; Thomas A; Borkowetz A; Stroh K; Thomas C; Haferkamp A; Höfner T; Boehm K
World J Urol; 2022 Dec; 40(12):2947-2954. PubMed ID: 36318314
[TBL] [Abstract][Full Text] [Related]
9. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
[TBL] [Abstract][Full Text] [Related]
10. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
[TBL] [Abstract][Full Text] [Related]
11. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
12. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
14. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
15. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
16. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
Hou Y; Jiang KW; Zhang J; Bao ML; Shi HB; Qu JR; Cheng G; Zhang YD
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):727-734. PubMed ID: 35067674
[TBL] [Abstract][Full Text] [Related]
17. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
18. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
20. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
